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INTRODUCTION 
HIV and AIDS 
The Human Immunodeficiency Virus (HIV) is a retrovirus of the lentivirus family. Lenti means 
slow, and the name reflects the long incubation period, the time it takes from infection until the 
associated disease starts developing. The virus is mainly transmittable through bodily fluids, 
primarily blood and semen. A person infected with the virus has a gradual inactivation of the 
immune system. Characteristically, the CD4+ T cells are depleted. This causes the disease Acquired 
Immunodeficiency Syndrome (AIDS). With their immune system in disarray the bearer of the virus 
is more susceptible to opportunistic infections and several, otherwise rare, types of cancer.  
AIDS is now a pandemic disease. In 2007, it was estimated that 33.2 million people lived with the 
disease worldwide, and that AIDS killed an estimated 2.1 million people, including 330.000 
children. Over three-quarters of these deaths occurred in sub-Saharan Africa.  
Several steps are being taken to combat this disease. One important step is health education 
campaigns that inform the public of how AIDS is transmitted, thereby trying to limit the number of 
people being exposed to the virus. Another step is the development of drugs to treat the disease. 
Research that gives us knowledge of the molecular mechanisms of how the virus interacts with its 
host will drive forward the development of novel therapies. No known therapy can completely rid 
the body of the virus. Several vaccines are currently in different stages of clinical trials in humans. 
These vaccines are, however, therapeutic vaccines, aimed at controlling the infection rather than 
preventing it (reviewed by Amara and Robinson, 2002). A combination of drugs called HAART 
(Highly Active Anti-Retroviral Therapy) has proved very efficient in stalling the disease, but there 
are serious problems with toxic side effects (Louie et al., 2002; http://hivmedicine.com/index.htm). 
A major problem in the development of treatments and therapies for HIV infection is the high 
frequency with which the virus mutates. Mutations also cause the changes that make the immune 
system unable to recognize the virus (Wei et al., 2003). The viral encoded reverse transcriptase 
protein (RT) transcribes genomic RNA to double stranded DNA, which is integrated into the host 
genome. RT does not have a proof-reading activity, and is the main cause of mutations of the virus 
(Preston and Dougherty, 1996). This accounts for the many different strains and subtypes of HIV.  
HIV is classified as two major types: HIV-1 and HIV-2. HIV-1 is the most common and infectious 
of these two, and can further be divided into 3 groups: M, N and O. HIV-1 Group M is by far the 
most important contributor to the AIDS pandemic and can further be divided into 10 subtypes, A-H 
and J-K (http://hiv-web.lanl.gov). When comparing the sequences of different strains of HIV with 
those of Simian Immunodeficiency Virus (SIV), the interspersion in the evolutionary tree (see 
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figure 1) suggests shared viral lineages (Hahn et al., 2000; Korber et al., 2000), and that HIV has 
arisen when SIV has been transmitted from its natural simian host to humans. It also suggests that 
this sort of transmission has occurred several times. For instance, it is likely that HIV-1 groups M, 
N and O have arisen from separate zoonotic transmissions of SIV. HIV-1 and HIV-2 are related to 
quite different strains of SIV, SIV from chimpanzees, SIVCPZ, and sooty mangabey, SIVSM, 
respectively. Despite its name, most strains of SIV do not cause disease in their natural host.  
 
 
 
Figure 1: Phylogenetic (i.e. evolutionary) tree of different strains of HIV-1 and SIV CPZ, showing how they are 
related. The length from one indicated point to another shows relative genetic distance. HIV-1 group M is the main 
cause of the global pandemic and all the subtypes within are likely to have descended after a single zoonotic transfer 
(cross-species transfer from the natural host, a non-human, to a human) of a simian virus. HIV groups N and O are 
likely to have arisen after separate zoonotic transmissions. SIV CPZ P.t.t.: strains of SIV found in Pan troglodytes 
troglodytes, a subspecies of chimpanzee. SIV CPZ P.t.s.: a strain of SIV found in a chimpanzee of the subspecies Pan 
troglodytes schweinfurthii. (Modified from Reeves and Doms, 2002) 
 
A sample from 1959 shows that HIV-1 was in a human population already at that time (Zhu et al. 
1998) and sequence analyses estimate that the last common ancestor of the HIV-1 M group existed 
in a human host some time between 1915 and 1941 (Korber et al. 2000).  
What effect the divergence in sequence between the different strains has on virulence, transmission 
rates and general epidemiology has not been clarified, but the different HIV-1 types all have the 
same basic structure (shown in figure 2), and the same life cycle (figure 4). 
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The physical and genetic structure of HIV 
A model of the virus particle is depicted in figure 2. It is spherical with a membrane that originates 
from the host cell plasma membrane. Located on the surface of the membrane is a protein called 
gp120 or the Surface protein (SU). It is anchored through gp41, the Transmembrane protein (TM). 
TM is embedded in the membrane. Underneath the plasma membrane is an icosahedron made by 
the Matrix protein (MA). Inside the icosahedron the Capsid protein (CA) forms a cone in the mature 
virus particle. This cone is called the core particle. Within this cone are the proteins Reverse 
Transcriptase (RT), Integrase (IN), Protease (PR), and Nucleocapsid (NC). The latter is associated 
with the two RNA copies of the HIV genome. This association serves to stabilize the genome. In 
addition the viral particle contains the viral proteins Nef, Vif, Vpr and p6, as well as several cellular 
factors (Frankel and Young 1998; Ott et al., 2000). Among these is the tRNA (tRNALys) that is 
used as primer for initiation of reverse transcription. 
 
 
 
 
Figure 2: Organisation of the HIV-1 virus particle, showing the most important parts 
 
Depicted in figure 3 is the organisation of the HIV-1 genome, an approximately 9200 bp long single 
stranded RNA. It contains the gag, pol and env genes. This is typical for all retroviruses. These 
genes encode polyproteins, which are cleaved by proteolysis into individual proteins. The Gag 
polyprotein is cleaved into the proteins MA, CA and NC that make up the core of the virion, as well 
as p6 found within the virion. Env encodes the membrane proteins SU and TM. Pol encodes the 
enzymes PR, RT and IN. The HIV genome further contains the genes for Tat and Rev, proteins that 
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regulate HIV gene expression, as well as genes for four accessory proteins, Nef, Vif, Vpr and Vpu. 
As seen in the figure, these additional proteins are encoded by separate and overlapping ORFs 
(Frankel and Young, 1998). 
 
Figure 3:  The HIV-1genome. The genes gag, pol and env encode polyproteins that are proteolytically cleaved to 
produce the mature virion proteins. The viral protease (PR) cleaves Gag and Gag-Polpolyproteins, while the Env 
polyprotein is cleaved by a cellular protease. Gag encodes the Matrix protein (MA), the major Capsid protein(CA), the 
Nucleocapsid protein (NC) and p6; from pol, Protease, Reverse Transcriptase (RT) and Integrase (IN); and from env, 
the surface subunit (SU) gp120 and the Transmembrane subunit (TM) gp41 are encoded. The regulatory proteins Tat 
and Rev, as well as the accessory proteins Vif, Vpr, Vpu and Nef are all encoded by their own open reading frames in 
the HIV-1genome. The Long Terminal Repeat, LTR, is used as a promoter. The HIV-1 mRNA contains several splicing 
sites. Fully spliced it encodes Tat, Rev and Nef proteins. The other proteins are expressed when Rev downregulates the 
splicing of this mRNA. The proteins encoded by gag and pol also have alternate names, based on their molecular 
weight. MA=p17, CA=p24, NC=p7,RT=p66/p51 (a dimer where the two subunits are differently cleaved), IN=p32, 
PR=p11. 
 
The life cycle of HIV 
 
The life cycle of HIV is outlined in figure 4. HIV-1 infects a cell as the plasma membrane of the 
virus particle fuses with the cellular plasma membrane. This is a result of the interaction between 
SU in the viral membrane and the cell-surface receptor CD4. The fusion of these membranes also 
requires a coreceptor. The coreceptor commonly used by HIV-1 is CXCR4, which is located on the 
surface of CD4 T Helper cells; or CCR5, which is located on the surface of macrophages and a 
subset of the CD4 T Helper cells (figure 5). Which coreceptor a virus can use determines its 
tropism. The fusion of viral and cellular membranes leads to the release of the viral core particle 
into the cytoplasm. The particle develops into a looser structure. Within this structure the RNA 
genome is reverse transcribed. This renders a linear double stranded DNA molecule. The 
transformed core particle, a DNA protein complex called the preintegration complex (PIC), moves 
from the cytoplasm into the nucleus. There IN integrates the viral DNA into a host chromosome, 
thus making the viral genome a stable genetic element of the infected cell, a provirus. 
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The first full-length viral mRNAs to be produced will for the most part be doubly spliced. These 
mRNAs encode the Tat, Rev and Nef proteins. Tat and Rev function in feedback loops and will 
travel to the nucleus. Tat will increase the production of functional HIV mRNAs through a 
mechanism discussed later. Rev transports unspliced and singly spliced viral mRNAs to the 
cytoplasm where the mRNAs are translated. This leads to the expression of the other HIV proteins.   
 
 
 
Figure 4: The HIV life cycle 
 
Full-length, unspliced mRNA transcribed from the provirus is packaged into the new virions and 
used as genomic RNA. It is also used as messenger RNA for synthesis of both Gag and Gag-Pol 
polyproteins. The latter is made when the ribosome shifts reading frames while translating this 
mRNA. This happens approximately every 20th round of translation. The Gag and Gag-Pol 
polyproteins will associate at the plasma membrane and initiate the assembly of the core particle. 
The plasma membrane where they assemble is enriched with the SU and TM proteins. These two 
proteins are formed as gp160 polyprotein and cleaved by a cellular protease in the Golgi. The core 
particle becomes encapsulated within plasma membrane as it is budded off from the cell. 
Maturation takes place during or immediately after the budding of this particle. A functional core 
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particle is formed in this process when the viral protease cleaves the Gag and Gag-Pol polyproteins 
(reviewed by Frankel and Young, 1998). 
 
 
Figure 5: HIV binding via cell surface receptor 
 
Immune response to HIV 
 
Exposure to a pathogen elicits innate or adaptive (acquired) immune responses. Innate responses are 
immediate and nonspecific, and do not result in immunological memory but limit damage before 
adaptive immune responses take effect. The latter develop over days to weeks after exposure to 
antigen, through clonal expansion and differentiation of B lymphocytes and T lymphocytes, which 
recognize antigen via specific binding of cell surface receptors. A proportion of antigen-specific 
lymphocytes differentiates into memory cells; these characteristically respond more rapidly 
following re-exposure to the stimulating antigen (a phenomenon exploited by active immunization). 
Adaptive immune responses to HIV are detectable in all infected individuals at some time and 
comprise antibodies and CD8+ (cytolytic) and CD4+ (helper) T cells.  
Following acute infection, HIV disseminates throughout the lymphoid system and replicates in a 
subset of CD4+ T cells, generating up to 1010 new virus particles per day. Within 2–3 weeks, the 
concentration of virions in the circulation (expressed as the number of copies of viral genomic 
RNA/ml plasma) reaches a peak of several million; this declines over the following months to a 
‘set-point’ or steady-state level. The set-point is predictive of the rate at which individuals progress 
to AIDS. The virus population at this point is not genetically homogeneous, but is a mixture of a 
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large number of genetically mutated strains, present because of a lack of ‘proof-reading’ by reverse 
transcriptase (the enzyme that makes DNA copies of viral genomic RNA). Although early immune 
responses determine the level of the viral load set-point, the high mutation rate of HIV is an 
important factor in the ultimate failure of the immune system to contain it.  
Antibodies specific responses to a range of HIV proteins typically develop over 4–6 weeks after 
infection, and their detection by enzyme-linked immunosorbent assay (ELISA) is the basis of the 
most widely used diagnostic test for HIV infection. During acute infection, the concentration of 
antibodies in the circulation may be too low to be detected by ELISA, and serological tests 
performed during this ‘window period’ may give a false-negative result. 
Although antibody binding of cell-free virus in the circulation and at mucosal surfaces contributes 
to the clearance of many viral infections, and pathogen-specific antibodies are typically a marker of 
protective immunity, this is not usually the case in HIV infection. Antibodies to structural proteins 
(Gag, p24 and p17) appear first, are non-neutralizing and do not generally persist. Antibodies with 
neutralizing capacity appear later and are detectable throughout the course of infection. They are 
predominantly targeted at one of three regions in the envelope protein that are crucial for viral entry 
into CD4+ T cells (Figure 6 ): 
 
 
Figure 6: Targets of the antibody response in HIV infection 
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• a variable region (V3 loop) of a subunit protein, gp120 
• the binding sites for CD4 and the chemokine receptors CXCR4 and CCR5 
• the transmembrane protein gp41. 
However, antibodies in the sera of HIV-infected individuals are principally directed at irrelevant 
regions of the envelope protein or at virion debris, and have weak neutralizing capacity.  
Over time, mutant viruses emerge that can evade a previously effective neutralizing response. 
Although this is indicative of immune selective pressure, there is no conclusive evidence that 
escape from neutralizing antibody responses is associated with disease progression; thus, they 
appear to contribute little to the control of HIV replication once infection is established. Certain 
individuals who remain symptom-free and maintain a low viral load and stable CD4 T cell count for 
up to 20 years (long-term non-progressors, LTNPs) have a strong neutralizing antibody response, 
but this is not a universal finding in this group of patients.  
 
Cellular immune responses  
 
HIV-specific cellular immune responses are triggered after virus entry into target cells and sub-
sequent synthesis of viral proteins. HLA (MHC) class I molecules on the cell surface display 
peptide fragments of degraded intracellularly derived viral proteins for recognition by specific T 
cell receptors (TCRs) on CD8+ T lymphocytes. CD4+ T lymphocyte TCRs recognize HLA class II-
bound peptides generated by the processing of shed viral proteins in specialized antigen-presenting 
cells, dendritic cells and macrophages. Engagement of the TCR with HLA–peptide complexes 
activates T cell effector functions. Generally, cytolytic CD8+ T cells lyse HIV-infected cells and 
secrete soluble factors, cytokines (interferon-γ (IFN-γ), tumour necrosis factor α) and chemokines 
(MIP-1α, MIP-1β and RANTES) that suppress virus replication or block viral entry into CD4+ T 
cells; CD4+ or T helper cells secrete cytokines that modulate the functions of other cell types 
(Figure 7). 
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Figure 7: Function of virus-specific T cells 
 
Most HIV-infected individuals develop vigorous, virus-specific CD8+ T cell responses that may be 
detectable within weeks of infection, before seroconversion. Evidence suggests that they are crucial 
for control of HIV replication in vivo. The appearance of cytolytic CD8+ T cells coincides with the 
decline in viraemia after primary infection. Virus variants that escape CD8+ T cell recognition 
emerge over time, indicating that selective pressure exerted by CD8+ T cell responses shapes the 
evolution of the virus population in infected individuals. Heterozygosity for HLA class I alleles, 
which determine selection of viral peptides for presentation to CD8+ T cells, or the presence of 
certain alleles (HLA B27 or B57), is associated with a lower set-point viral load and slower disease 
progression. Treatment of simian immunodeficiency virus (SIV)-infected macaques with a 
monoclonal antibody to deplete CD8+ T cells results in a marked increase in SIV viraemia that is 
suppressed when CD8+ T cells are restored.  
CD4+ T cells are conventionally detected by in vitro T cell proliferation assays. Because CD4+ T 
cell proliferative capacity is lost early in infection in most HIV-infected individuals, it was assumed 
that these cells contribute little to the control of HIV replication. However, sensitive assays 
detecting cytokine release indicate that HIV-specific CD4+ T cells are present during chronic 
infection, and recent research suggests that the type and range of cytokine secretion may correlate 
with viraemia control. The presence of CD4+ T cells secreting the growth factor interleukin-2 (IL-
2), or cytokines including IL-2 and IFN-γ, is more favourable than that of cells secreting IFN-γ 
alone. Strong HIV-specific CD4+ T cell proliferative responses, in tandem with vigorous CD8+ T 
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cell responses, have been seen in LTNPs and this, together with the role of CD4+ T cells in 
facilitating and maintaining both antibody and CD8+ T cell effector and memory responses in other 
viral infections, suggests that effective CD4+ T cell help is important for containment of HIV. 
 
Immune system failure to contain HIV  
 
Less than 2% of infected individuals can be reliably defined as LTNPs; most of them present 
progressive CD4+ T cell depletion and develop symptoms related to immunodeficiency after a 
median of 10 years, despite evident HIV-specific immune responses. There are many reasons why 
the immune system fails to contain HIV replication. By establishing latent infection in long-lived 
CD4+ T cells, HIV can remain invisible to CD8+ T cells; therefore, infected cells are not destroyed. 
Virus replication can be initiated in these cells at a later stage, generating new infectious virions.  
Specific properties of the virus envelope protein account for the resistance of HIV to antibody 
neutralization; extensive glycosylation and shielding of crucial antibody epitopes by non-
immunogenic carbohydrate molecules prevents antibody blockade of the key sites in the envelope 
required for viral entry into CD4+ cells. Antibodies to the V3 loop (a major neutralizing 
determinant and one of the most antigenically variable regions of the envelope protein) are 
generally specific to a single HIV isolate and therefore exhibit poor neutralizing activity against 
other virus variants. The CD4-binding domain is highly conserved between virus strains, in contrast 
to the V3 loop, but antibodies specific to this region of the envelope exhibit weak neutralizing 
activity.  
Antigenic variation within or close to CD8+ and CD4+ T cell epitopes can affect either the capacity 
of viral peptides to bind to MHC molecules, or the ability of TCRs to recognize the MHC–peptide 
complex. A single amino acid substitution may be sufficient to enable virus escape from T cell 
recognition, at any stage in the course of infection. The HIV Nef protein reduces expression of 
MHC class I molecules on the infected cell surface, thereby potentially impairing presentation of 
viral peptides to CD8+ T cells, though the contribution of this mechanism to immune failure is not 
known. HIV-specific CD8+ T cells may exhibit antiviral functions such as IFN-γ-secreting 
capacity, yet fail to proliferate in response to viral antigenic stimulation or exhibit impaired 
cytolytic capacity.  
Functional impairment of CD4+ T cells is evident even before the absolute CD4+ T cell count has 
declined significantly. This may be attributable to preferential infection of HIV-specific CD4+ T 
cells and to replication of virus occurring predominantly in recently activated cells (i.e. those 
responding to the infection). 
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Tat protein 
 
Tat (trans-activator) proteins are early RNA binding proteins regulating lentiviral transcription. 
These proteins are necessary components in the life cycle of all known lentiviruses, such as the 
human immunodeficiency viruses (HIV).  
In acute infection of T cells by HIV, Tat is released extracellularly by infected cells [Ensoli et al. 
1990; Westendorp et al. 1995] and is taken up by neighbour cells [Ensoli et al. 1993; Barillari et al. 
1992]. Tat is also immunogenic and antibodies (Ab) against Tat have been found to correlate with 
delayed disease progression [Reiss et al. 1990; Zagury et al. 1998; Re et al. 1995] and may exert 
protective effects by inhibiting both HIV replication and the effects of extracellular Tat [Ensoli et 
al. 1993; Re et al. 1995]. Moreover, Tat is efficiently taken up by monocyte-derived dendritic cells 
(MDDCs), promotes their maturation and antigen (Ag)-presenting functions [Fanales- Belasio et al. 
2002] directing Th1 and CTL responses against itself and other Ags since it enters the major 
histocompatibility complex (MHC) class I pathway [Kim et al. 1997]. Finally, vaccination of 
monkeys with a biologically active Tat protein or DNA has been shown to be safe, immunogenic 
and to contain infection with the highly pathogenic SHIV89.6P [Cafaro et al. 2000;Ensoli et al. 
2000; Dominici et al.2003 ] 
Tat proteins are thus ideal targets for drugs intervening with lentiviral growth. The consensus RNA 
binding motif (TAR, trans-activation responsive element) of HIV-1 is well characterized. 
Regarding Tat sequence in general, sequence regions corresponded to structural domains of the 
protein. The Tat protein contains 86 amino acids. It exhibits a hydrophobic core of 16 amino acids 
and a glutamine-rich domain of 17 amino acids. Part of the NH2 terminus, Val4 to Pro14, is 
sandwiched between these domains. Two highly flexible domains correspond to a cysteine-rich and 
a basic sequence region. The 16 amino acid sequence of the core region is strictly conserved among 
the known Tat proteins (Bayer et al.1995)  
 
 
 
Figure 8: Tat protein sequence( Bioafrica) 
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Figure 9: Tat protein domain 
 
 
 
Env protein 
 
The HIV envelope glycoproteins (Env) are organized on virions as trimeric spikes of noncovalently 
associated heterodimers of gp120 and gp41 that are assembled following cleavage of 
a gp160 precursor molecule. 
 
 
Figure 10: gp120-gp41 heterodimers assembling 
 
The Env trimer mediates viral tropism and entry and is the target for neutralizing antibodies. Each 
virion contains approximately 5–10 spikes (Roux et al. 2007), although it has been estimated that 
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only one spike may be needed to mediate viral entry (Yang et al. 2005). Gp120 contains highly 
conserved binding sites for CD4 and a coreceptor, either CCR5 or CXCR4 (Pierson et al. 2003). 
Following engagement by CD4, gp120 undergoes extensive conformational changes that lead to 
coreceptor binding and release of gp41 to interact directly with the cell membrane. Thereafter, gp41 
molecules undergo a cooperative structural rearrangement within the trimer that draws the viral and 
cell membranes together, initiating fusion and enabling viral entry.  
 
 
 
Figure 11: Conformational changes occuring upon CD4 binding. 
 
All of these steps are critical for infection; thus, all are potential targets for antibody inhibition, but 
the Env has evolved an extensive array of defenses that either prevent neutralization or enable 
escape variants to emerge once neutralizing antibodies are made. Sites on gp120 for CD4 and 
coreceptor binding are located on a central core formed by an inner and outer domain that, in the 
context of an Env trimer, are surrounded by an extensive array of carbohydrates comprising up to 
50% of gp120’s molecular mass (Wyatt et al. 1998; Kwong et al. 1998; Kwong et al. 2009;). 
Because these carbohydrates are synthesized by host glycosylation machinery, they are largely 
nonimmunogenic and constitute an exposed but immunologically silent face (Wyatt et al. 1998). In 
addition, on a trimer, gp120 contains externally oriented variable loops (V1, V2, V3, and V4) that 
participate in poorly understood cooperative interactions to protect underlying core domains from 
antibody binding. Although these loops are highly immunogenic, they can tolerate extensive genetic 
diversity, and mutations within these sites, resulting from HIV’s highly error-prone reverse 
transcriptase, enable the virus to escape neutralization (Frost et al. 2005). The V3 loop, which 
largely determines tropism for CCR5- or CXCR4-expressing CD4 cells and participates directly in 
coreceptor binding, was once viewed as the principal neutralizing determinant for antibodies 
(Hartley et al. 2005). 
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Figure 12: Env protein domains 
 
However, it is now appreciated that in transmitted HIV isolates, this loop, although highly 
immunogenic, is largely concealed prior to CD4 attachment and binds poorly to antibodies (Binley 
et al.2004; Lusso et al. 2005; Li et al. 2005; Davis et al. 2009). Conformational defenses play 
additional roles. Prior to CD4 binding on the cell surface, the flexibility of gp120 may limit the 
formation of neutralization epitopes (Kwong et al. 2002); after CD4 binding, domains that are 
induced and that help to form a coreceptor binding site on the gp120 core are sterically restricted 
and inaccessible to antibodies (Labrijn et al. 2003). There are also Env surfaces that are not exposed 
on the trimer (i.e., the “non-neutralizing” face of gp120), which are highly immunogenic but elicit 
antibodies that cannot bind to an intact Env trimer (Wyatt et al. 1998). These domains, along with 
disrupted spikes on virions, are likely exposed in the context of gp120 shedding and viral debris 
from infected cells and may serve as immunodominant decoys to divert immune responses from 
potentially more efficacious but less immunogenic neutralization epitopes (Moore et al. 2006). 
Given the sparse distribution of Env trimers on a virion, antibodies also may be unable to bind with 
both of their Fab domains, further diminishing their potency (Klein et al. 2009). In general, it has 
become increasingly apparent that to neutralize HIV an antibody must bind to the Env trimer (27–
29 Fouts et al. 1997; Kim et al. 2005; Sattentau  et al 1995), and an understanding of potential 
binding sites on this structure is clearly needed.( Hoxie 2010) 
Gp140 is a soluble protein with gp120 and gp41(containing the trimerization domain) fused 
together, it is the ectodomain of gp160, thus is an Env form stabilising the trimer. 
A mutant of gp140 with a deletion in V2 loop further stabilises the trimer and also increases the 
immunogenicity of certain neutralization epitopes. Antibodies against this form reduce viral 
replication (Srivastava et al., 2003).  
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Tat-Env 
 
Some studies suggest that extracellular Tat is partially sequestered by heparan sulfate 
proteoglycans. As a consequence, Tat is concentrated on the cell surface and protected from 
proteolytic degradation, thus remaining in a biologically active form. 
It has been shown that Tat binds the surfaces of both HIV-1–infected and surrounding uninfected 
cells. Moreoever, there are evidences for a specific interaction between Tat and the gp120 envelope 
protein, which enhances virus attachment and entry into cells.  
Basic science studies and pre-clinical studies are ongoing with the aim to identify and characterize 
the immunological interaction between Tat and Env, and to identify the role of this interaction, to 
finally  prevent HIV infection and/or progression to AIDS.( Marchio et al 2005) 
 
 
 
 
Figure 13: Schematic representation of Tat/Env interaction. 
 
 
HIV protein-based vaccine  
 
When compared to other viruses, HIV has a number of differences that makes it particularly 
difficult to fight. Over the past 20 years, most of the efforts in HIV vaccine development have 
focused on using HIV's Envelope protein (gp120 or Env) in vaccines, in the attempt to induce anti-
Env antibodies able to neutralise the infection of the cell by HIV. Theoretically, Env-specific 
antibodies would prevent entry of the virus into cells. If successful, the vaccine would provide 
sterilizing immunity, which protects the vaccinated person from becoming infected with HIV. 
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However, historically, results of Env-based vaccines in pre-clinical and clinical trials have been 
largely disappointing. In fact, an Env-based vaccine from Vaxgen failed to protect volunteers in 
phase III clinical trials (Pitisuttithum et al.2006).  
Env-based vaccine candidates are believed to have failed because the envelope proteins of the HIV 
virus mutate rapidly. Because of this characteristic, the immune system is not able to recognize and 
fight all the variants of the virus. This is similar to what happens with influenza each year, but HIV 
mutates much faster than influenza. 
More recently, other approaches have been developed aimed at inducing T-cell mediated responses 
against other HIV antigens. However also these approaches failed. An example of this is the recent 
trial from Merck, based on gag, pol and nef genes, that failed to protect volunteers. These last 
results come from an international study partly funded by the US National Institutes of Health 
(NIH). 
Regulatory genes, including tat, express proteins soon after infection and are essential for virus 
replication and pathogenesis. They are also more highly conserved among the different types of the 
HIV virus found worldwide than are other HIV genes. In addition, Tat is released by infected cells 
and instructs cells in close proximity to become more prone to infection. These features make the 
Tat protein a logical candidate for vaccine development. 
Tat + Env combination is a vaccination regimen by which individual formulations of Tat and Env 
proteins will be administered in combination. The separate formulations contain, respectively, Env 
and biologically active Tat . 
Preclinical studies in monkeys indicate that the Tat/Env combination is safe and superior at 
inducing neutralizing antibodies and, at the same time, increase the breathe of the immune-
responses to the single components.  
Based on these findings, the scientists are starting Phase I studies with candidate vaccines that 
combine Tat and Env.[ http://www.hiv1tat-vaccines.info/index.php] 
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AIM OF THE THESIS 
 
 
Knowledge of the unliganded trimeric Env structure is key point for understanding of viral entry 
and immune escape and for the design of vaccines to elicit neutralizing antibodies. 
The structure of the whole Env complex has remained unsolved till now, due to its complexity and 
its instability in solution. Structural informations are available only on portion of it, in particular on 
gp41, for which are available crystallographic data since 1999 (Yang et al. 1999). Crystallographic 
structures of monomeric gp120 core from SIV (Chen et al. 2005) and from HIV-1, lacking the 
hypervariable loops and N- and C-termini and complexed with specific ligands (Kwong et al.1998), 
have been solved. Moreover HIV-1 gp120 core containing the V3 loop structure has been 
determined (Huang et al.2005).  
Most recently a great tool came from the use of cryo-electron tomography, that was employed to 
determine the three dimensional structure of trimeric Env as complex in situ, on virion particles 
(Liu et  al. 2008; Zanetti et al.2006). 
The aim of this work is to try to bridge the gap between the atomic level structures data derived 
from crystallographic studies and the three-dimensional reconstruction by surface mapping. 
By the combined use of chemical modification of cysteine and lysine residues, proteolysis, HPLC 
and mass spectrometry, we mapped the accessible aminoacids on the surfaces of monomeric gp120 
and on trimeric complex of gp140, that is formed by the external domains of the HIV-1 envelope 
glycoprotein (gp120 and gp41 ectodomain ).  
From the results useful informations about gp120 structure and how monomers joint together to 
form trimeric complex are expected. 
By the same approach it will be possible to well characterize the interaction surface between Env 
and Tat protein. This possibly will be a start point for developing a new double protein-based 
vaccine to employ at prophylactic and therapeutic level. 
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MATERIALS AND METHODS 
 
gp120 and gp140  
Recombinant monomeric Gp120 SF160ΔV2 and trimeric Gp140 SF160ΔV2 were kindly provided 
by ISS (Istituto Superiore di Sanità). 
 
Counting the number of modified lysine residues of gp140 and gp120 envelope proteins 
The reaction of 2,4,6-trinitrobenzenesulfonic acid (TNBS) with amino groups has been used in 
studying the solvent exposure of lysine residues in gp140 and gp120 envelope proteins. 
 
 
 
 
  Figure 14: scheme of TNBS reaction 
 
70 μl of gp120 protein or gp140 (0,92 μg / μl) was incubated for minutes at 37°C with 5.0 mM  
TNBS solution (solved in sodium bicarbonate 0,8 M and NaOH for adjusting pH value at 7.5 ). 
Reaction was stopped by adding 2-mercaptoethanol at 37°C for 5 minutes. 
Removal of TNBS excess was achieved by use of MicrospinTM G-25 Column (Illustra TM  - GE 
Healthcare). 
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After freeze drying, the sample was resuspended in a solution of: 8 M urea buffered with 50 mM 
phosphate buffer, pH 7.8, then iodine-acetate (final concentration 5 mM) and tris-(2-carboxyl-
ethyl)- phosphine (TCEP, final concentration 5 mM) were added and the sample was stored for 1 
hour at 60°C. The excess of reagents was removed with a MicrospinTM G-25 Column (Illustra TM - 
GE Healthcare) pre-equilibrated in 20 mM phosphate buffer, pH 7.2. 
The reduced and caboxymethylated sample was incubated overnight at 37°C with 2U of N-
glycosidase F (Roche) to cleave N-linked carbohydrates. 
Then after freeze drying, sample was resuspended in 15 μl of 8 M urea and incubated for 30 
minutes at 37°C. Urea concentration in the sample was adjusted to 2 M by adding 50 mM 
phosphate buffer, pH 7.8. 
The sample was digested 5 hours at 37°C with chimotrypsin 5% w/w and the peptides were 
separated by HPLC 
 
Labelling of cysteine residues of gp120 and gp140 envelope proteins 
  
 
 
 
 
  Figure 15: scheme of SBDF reaction 
 
 
 
 
For the labelling of solvent-exposed disulfide was used the reduction by Tris-(2-carboxyl-ethyl)- 
phosphine (TCEP) and the modification of reduced cysteines by  7-fluorobenzo-2-oxa-1,3-diazole-
4-sulfonate (SBD-F). 
To 50 µL gp120 protein or gp140 (0,92 μg/μl) envelope protein, SBDF (5.0 mM final 
concentration) and TCEP (0.22 mM final concentration) were added and the reaction mixture was 
incubated for 30 min at 37°C in the dark. Reaction was stopped by adding 2-mercaptoethanol at 
37°C for 5 minutes. The volume of the reaction mixture was adjusted at 100 µL by adding 50 mM 
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phosphate buffer, pH 7.0. Removal of SBDF excess was achieved by use of MicrospinTM G-25 
Column (Illustra TM  - GE Healthcare). 
The sample was reduced and carboxymethylated, and treated with -glycosidase F as described 
above. Digestion was carried out at 5% w/w chymotripsin in 2.0 M urea for 5 h at 37 °C. 
 
 
HPLC 
All runs were carried out on Agilent Technologies 1200 Series HPLC System utilizing an Hypersil 
C18 reversed-phase analytical column (150 X 4.6 mm, 5 µm particle-size, Agilent), protected with 
an Alltech C18 guardcolumn (7.5 X 4.6 mm, 5µm particle-size). The detectos was setted at 346 nm 
for the TNBS-labelled peptides and at 380 nm for the SBDF-labelled peptides. 
The samples were eluted at a flow rate of 1. mL/min by gradient of water with 0,1 % Trifluoroacetic 
acid (TFA) (Sol A) and acetonitrile with 0.09% TFA (Sol B) with the following program 
Time %A %B 
0 100 0 
5 100 0 
60 40 60 
80 20 80 
85 20 80 
 
 
Mass spectrometry (MS) 
ESY mass spectrometry was carried out in the department of Chemistry of the University of Ferrara 
in collaboration with Dott. Alberto Cavazzini e Nicola Marchetti 
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RESULTS AND DISCUSSION 
 
To verify the better conditions for a reproducible and exhaustive digestion of  gp120 and gp140 
several proteases and digestion conditions were tested. The results obtained with subtilisin and V8 
proteases were scarcely reproducible, and the better results were obtained with chymotripsin in the 
presence of 2.0 M urea. Despite it is reported that under these conditions some of the protese-
sensitive bonds are not hydrolysed, the HPLC profiles were highly reproducible 
The labeling of gp120 or gp140 by SBDF was studied at different TCEP concentrations. The lower 
concentration used was 73.0 μM, nearly stoichiometric with the disulfide bonds present in the 
proteins, and  under these conditions only a very faint labeling occurs. By increasing the TCEP 
concentration to 0.22 mM ( a three fold excess) a significant increase of the extent of labeling was 
observed, without the appearance of new peaks. A further increase of the TCEP concentration 
causes an extensive labeling, therefore all the experiments were performed at 0.22 mM TCEP. 
The HPLC profile of the chymotrypsin digest of Gp120 labeled with TCEP/SBDF (Fig.16) is 
indistinguishable from that of the digest of Gp140. This indicates that the disulfide bonds easily 
accessible to the reagents are not at the trimer interface neither in the C-terminal part of Gp140.  
 
 
 
 
 Figure 16: HPLC trace of the chymotryptic digest of Gp120 (blue) and Gp140 (red) labeled with SBDF 
 
Analysis by HPLC/MS of the main peaks allows the identification of ten SBDF-modified peptides, 
(Table). 
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Cisteine Peptide mass found mass calculated 
53** casdakay 1026.15 1026.0 
118 slkpcvkl 1085.42 1085.25 
125 tplcvtl 944.13 944.02 
155** kncsf 795.69 795.75 
204 ncntsv 834.62 834.76 
213 itqacpkv 1057.29 1057.16 
226 hycapagf 1062.95 1063.08 
255 qcthgi 855.86 855.83 
390 ycnstqlf 1025.9 1026.0 
417 tlpcrikqi 1269.37 1269.46 
 
Table 1: The mass unit is Da; **, these labeled cysteine residues are not accompanied with the correspondent 
cysteine in the disulfide bridge (see text) 
 
The data indicate that at least six disulfides are reduced, but two peptides escaped the detection. In 
fact for the disulfide C53-C73 only the peptide corresponding to the labeled cysteine 53 was found 
in the major peaks. The same occurred for the disulfide between C130 and C155, where only a 
labeled peptide corresponding to C155 was found. This unexpected result could be due to different 
factors. In the native protein the reduction of disulfide could allow local conformational changes 
resulting in a partial shielding of a cysteine. Otherwise incomplete digestion as well as 
fragmentation of a peptide in multiple fragments could spread the modified cysteine in several low 
intensity peaks. In any case if one cysteine is labeled this means that the disulfide is accessible to 
the reagents. 
The reactive disulfides are located in the N-terminal region (C53-C73), in the V1-V2 loops (C118-
C213, C125-C204, and C130-C155), between β4 and β8 (C226-C255) and in the V4 loop (C390-
C417) between β17 and β19.  
Three disulfides appear stable and unlabelled at significant extent under the mild reducing 
conditions used: C236-C247, located in the loop between β5 and β6; C304-C338, between β12 and 
β13 closing the V3 loop; C383-C464, between β16 and β22. 
Only four of six reactive disulfides can be identified in the three-dimensional structure of Gp120, 
because all the X-ray structures reported until today are of the core structure, lacking both the N-
terminal part and the V1-V2 loops. 
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The labeling of gp120 and gp140 with TNBS was carried out at keeping the final concentration of 
the reactive at 5.0 mM, and increasing progressively the incubation time. Up to 5 min of incubation 
the HPLC pattern is similar, with the height of the peaks increasing by increasing of the incubation 
time. Longer incubation times cause an extensive labeling, suggesting that also buried residues 
become accessible 
Also the HPLC profiles of the chymotrypsin digest of Gp120 and Gp140 labeled with TNBS are 
very similar (fig. 17).  
 
 
 
 
 
Figure 17: HPLC trace of the chymotryptic digest of Gp120 (blue) and Gp140 (red) labeled with TNBS 
 
Within the major peaks, 18 are identical in both proteins, while four additional peaks are found in 
Gp140 and on peak, present in Gp120, is absent in gp140. The major common peaks containing 
labeled lysine residues were identified by HPLC/MS. The labeled peptides found both in Gp120 
and in Gp140 are reported in Table 2.  
 
 
 
 
 
 
 29 
 
Lysine peptide Mass found Mass calculated 
32  ekl 601.62 601.58 
45 ygvpvwkeatttl 1678.02 1677.95 
120 kl 472.44 472.45 
153 drgeikncsf 1439.57 1439.51 
159 kvgagkl 1097.04 1097.11 
200 gagkli 770.81 770.85 
290 tdnakti 975.05 975.0 
297 qlkesvei 1158.17 1158.27 
350 kqiv 699.76 699.75 
355 tkl 573.52 573.57 
420 pcrikqi 1128.31 1128.26 
431 qevgkam 975.15 975.08 
459 trdggkei 1088.19 1088.14 
485-487 kykvv * 1091.85 1091.96 
490 vki 581.49 581.54 
 
           
Table 2: *Both mass corresponding to the double labeled peptide (1091.96) and single labeled peptide (848.96) were 
found. 
 
Only 16 peptides were identified, and six are located in the N-terminal part and in the V1 loop. The 
single lysine present in the V3 loop was not labeled. K120 and K431 are respectively in β2 and β21, 
two of the four strands of the sheet involved in the CD4 binding, that are described to undergo a 
remarkable conformational change in response to CD4 binding. Only four of the lysine identified 
are highly conserved in different HIV strains, the two already discussed, K120 and K431, plus 
K350, located in α2, and K487 in β25. All other labeled lysines show a variable degree of 
substitutions, indicating that these residues are not critical for the structure of the proteins.  
All the accessible residues identified are highlighted in the following sequence, where the variable 
loops V1, V3, V4 and V5 are evidenced. The gag sequence stays for V2. 
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28 sav  
31 eklwvtvyyg vpvwkeattt lfcasdakay dtevhnvwat hacvptdpnp qeivlenvte  
91 nfnmwknnmv eqmhediisl wdqslkpcvk ltplcvtlhc tnlknatntk ssnwkemdrg  
151 eikncsfkv gag k  
201 lincntsvit qacpkvsfep ipihycapag failkcndkk fngsgpctnv stvqcthgir  
261 pvvstqllln gslaeegvvi rsenftdnak tiivqlkesv einctrpnnn trksitigpg  
321 rafyatgdii gdirqahcni sgekwnntlk qivtklqaqf g nktivfkqs sggdpeivmh  
380) sfncggeffy cnstqlfnst wnntigpnnt ngtitlpcri kqiinrwqev gkamyappir  
440) gqircssnit gllltrdggk eisntteifr pgggdmrdnw rselykykvv kieplgvapt  
500) kaissvvqse ks  
 
 
The position of the labeled residues in the three-dimensional structure of Gp120 is shown in figure 
18 and 19. Also in this case the labeled lysine located in the N-terminal and in the V1 loop are not 
visible on the X-ray structure.  
 
 
 
 
Figure 18: Identification of the labeled residues in the three-dimensional structure of Gp120 from HIV bound to CD4. 
Reactive lysines are red, reactive cysteines orange, predicted glycosylation sites green, and residue not labeled blue. 
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Figure 19:Identification of the labeled residues in the three-dimensional structure of free Gp120 from SIV. Reactive 
lysines are red, reactive cysteines orange, glycosyl residues green. 
 
A first control of the quality of the data comes from the observation that the sites of interaction 
between Gp120 and CD4 are all labeled. The protein surface involved in the receptor recognition is 
obviously exposed, thus an extensive labeling is expected. From the X-ray structure of the complex 
with CD4 it appears that several part of the Gp120 are involved in the receptor recognition. These 
parts are β2, β3 and the loop connecting the two strands, and both cysteines and lysines are labeled. 
The loop between β10 and β11 and the sheets β19, β20 and β21 are equally labeled (Fig 20). 
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Figure 20:Two view of the CD4 binding site on Gp120 (pink). The other colors are the same of figure 3. 
 
The other major sites of modification are the N-terminal part and the V1 loop, both absent in the 
three-dimensional structure, the V5 loop, and the sheet β25. The V4 loop does not present neither 
cysteines or lysines, so it is impossible to know whether is exposed. The V3 loop present a lysine, 
but, as already pointed out, it is not labeled. This suggests that the V3 loop is, at least partially, 
shielded from the solvent.  
An examination of the overall structure evidences large parts of the molecule not accessible to the 
reagents. In fact the reactive residues appear clustered mainly in two parts: the N- and C- terminal 
part, that are supposed to face the Gp41 and the viral membrane, and the external part, where is 
located the CD4 binding site. 
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Figure 21:View of the reactive/non reactive residues. Each figure is rotated by 90°  
 
 
Despite the distribution of reactive residues on the three-dimensional structure is not uniform, a 
significant restrain can be imposed in the building of the trimer structure. However there are still 
several uncertainty, due to the lack of a significant part of the protein in the X-ray structure. For 
 34 
 
example about 50 amino acids are lacking at the N-terminal part. These amino acid are solvent 
exposed, and could shield some part of the molecule. 
Nevertheless some preliminary conclusion can be drawn. When the X-ray structure of Gp120 was 
fitted into the shape of the Env trimer, obtained by cryo-electron tomography ( Zanetti et al, PLOS 
2006), two possible conformations were found: one with the V3 loop exposed to the solvent, and 
another with the loop buried. Surface labeling data suggest that the model with V3 loop buried is 
more consistent. 
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PART II: 
role of hexose-6-phosphate mutarotase from 
Trypanosoma brucei in oxidative stress 
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INTRODUCTION 
 
 
Parasites 
 
Parasitic protozoa infect hundreds of millions of people every year and are some of the most 
important causes of human misery. Trypanosomes are a group of kinetoplastid protozoa 
distinguished by having only a single flagellum. Members of this group parasitize virtually all 
animal groups as well as plants and insects. Three distinct kinetoplastids cause human disease: 
various species of  Leishmania cause the Leishmaniasis, Trypanosoma cruzi  and Trypanosoma 
brucei are respectively , the causative agent of Chagas Disease and African sleeping sickness. All 
three are parasites of the blood and/or tissues of the human host and are transmitted by arthropod 
vectors. 
Currently the Leishmaniasis, prevalent in four continents, are considered to be endemic in 88 
countries, 72 of which are developing countries. It’s transmitted by the bite of certain species of 
sand fly.Occurring in several forms, the disease is generally recognized for its cutaneous form 
which causes non-fatal,disfiguring lesions, although epidemics of the potentially fatal visceral form 
cause thousands of deaths. 
Chagas disease occurs exclusively in Latin America in particular in the poor, rural areas of Mexico, 
Central America, and South America; it’s transmitted via faeces of a bug belonging to the family 
Triatominae. 
The symptoms of Chagas disease vary over the course of the infection. In the early, acute stage, 
symptoms are mild and usually produce no more than local swelling at the site of infection. As the 
disease progresses, over the course of many years, serious chronic symptoms can appear, such as 
heart disease and malformation of the intestines. If untreated, the chronic disease is often fatal. 
Current drug treatments are generally unsatisfactory; available medications are highly toxic and 
often ineffective, particularly those used to treat the chronic stage of the disease. 
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Human African Trypanosomiasis 
 
Human African Trypanosomiasis (HAT), also known as Sleeping sickness, is caused by T. brucei. 
It’s transmitted to humans by tsetse fly (Glossina Genus) bite which have acquired their infection 
from human beings or from animals harbouring the human pathogenic parasites. Although 
epidemics of sleeping sickness were more rampant in the past, the most recent World Health 
Organisation (WHO) estimates put 60 million people at risk of HAT today with approximately 
500,000 people currently with infections. The disease is discontinuously spread over 9 million 
square kilometers and affects populations across 37 sub-Saharan countries. 
 
H A T takes two forms, depending on the parasite involved. 
? T. brucei gambiense (T.b.g.) is found in west and central Africa. This form represents more 
than 90% of reported cases of sleeping sickness and causes a chronic infection. A person 
can be infected for months or even years without major signs or symptoms of the disease. 
When symptoms do emerge, the patient is often already in an advanced disease stage when 
the central nervous system (CNS) is affected.  
? T. brucei rhodesiense (T.b.r.) is found in eastern and southern Africa. This form represents 
less than 10% of reported cases and causes an acute infection. First signs and symptoms are 
observed after a few months or weeks. The disease develops rapidly and invades the central 
nervous system.  
A third sub-specie, T. brucei brucei, does not infect humans, but it causes a disease called Nagana 
in native antelopes, domestic livestock and other African ruminants with a high economic impact 
for local agriculture.  
There are two stages in sleeping sickness; the early stage refers to the hemolymphatic infection, and 
the late stage refers to infection of the CNS.  
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   Fig. 1: Distribution of Human African Trypanosomiasis 
 
 
The development of late stage sleeping sickness may not occur for decades in West African 
sleeping sickness, and a patient may only suffer mildly from fatigue due to the occasional rises of 
parasites in the blood. However, East African sleeping sickness is far more virulent, and can 
develop into late stage disease within weeks. Although symptoms and signs associated with nervous 
system involvement are varied for both East and West African sleeping sickness; advanced disease 
epileptic attacks, maniacal behavior, somnolence and coma are some typical late stage symptoms. 
Both treatment options and survival rates are drastically reduced once the trypanosomes infect the 
CNS. 
There is no vaccine available to prevent this disease and the possibility of developing one is still 
very remote, due to the periodic antigenic variation of the Variable Surface Glycoprotein (VSG) 
coat. 
Only four parental drugs are registered for the treatment of Human African Trypanosomiasis: 
pentamidine, suramin, melarsoprol and eflornithine. Three of them were developed over 50 years 
ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable 
toxicity, poor efficacy, undesirable route of administration (parental only) and drug resistance.  
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Pentamidine and suramin are used in the first or early stage of T.b.gambiense and T.b. rhodesiense 
infections, respectively. Melarsoprol is used in the second or advanced stage of both form of the 
disease and eflornithine is only used in the second stage of the T.b.gambiense infections since it has 
been found not to be effective in the disease due to T.b rhodesiense. 
This lack of effective, safe and affordable pharmaceuticals to control this disease, that cause high 
mortality and morbidity among poor people in the developing countries, underlines the urgency to 
find new drugs. 
The pharmaceutical industry argues that research and development is too costly and risky to invest 
in low-return neglected diseases; public and private initiatives have tried to overcome this market 
limitation through incentive packages and public-private partnerships. The lack of drug research 
and development for "non-profitable" infectious diseases will require new strategies. No sustainable 
solution will result for diseases that predominantly affect poor people in the South without the 
establishment of an international pharmaceutical policy for all neglected diseases. But in recent 
years research has produced many data to identify enzymes, other proteins and peculiar organelles 
as potential drug targerts  
 
The Trypanosoma brucei 
 
African trypanosomes are extracellular organisms, mono-flagellated protozoa with a complex life 
cycle involving an obligate change between an insect and a mammalian host. 
T. b. gambiense and T. b. rhodesiense are morphologically indistinguishable, measuring 25-40 µm 
in length. Infection in the human host begins when the infective stage, known as the metacyclic 
stage, is injected intradermally by the tsetse fly. The organisms rapidly transform into blood-stage 
trypomastigotes (long, slender forms), and divide by binary fission in the interstitial spaces at the 
site of the bite wound. 
Trypanosomes have a single specialized mitochondrion in which all of the DNA is localized in the 
kinetoplast, which is a part of mitochondrion adjacent to the flagellar pocket. Kinetoplast DNA or 
kDNA exists in two forms: mini-circles and maxi-circles. Mini-circle DNA encodes guide RNAs 
that direct extensive editing of RNA transcripts post-transcriptionally. Maxi-circle DNA contains 
sequences that, when edited, direct translation of typically mitochondrially-encoded proteins. 
kDNA undergoes repression and activation so that the trypanosome can switch its pattern of 
respiration to match its host’s energy source.  
Cellular features of the trypanosomes include a single flagellum that emerges from the flagellar 
pocket, the region to which endo- and exocytosis is limited. 
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The nuclear DNA is organized in separate chromosomes where the genes are organized in long, 
polycistronic transcription units. The genes are separated by only a few hundred base pairs and are 
without introns. The polycistronic precursor transcripts are processed into mRNAs by trans 
splicing, in which each transcripts obtains a capped leader of 39 nucleotides and a 3’ poly A tail. In 
T.brucei only four promoters are known, one is responsible for transcription of spliced leader RNA, 
one for rRNA and the other two direct transcription of VSG and Procyclin. 
 
Fig. 2: Schematic rappresentation of T.brucei 
The surface of the trypanosome is covered by a dense coat of Variable Surface Glycoprotein (VSG), 
which allows persistence of an infecting trypanosome population in the host. 
Periodic antigenic variation allows variants expressing a new VSG coat to escape the specific 
immune response raised against the previous coat.  
Sequencing of the T. brucei genome has revealed a huge VSG gene archive, made up of thousands 
of different VSG genes. It is estimated up to 10% of the T.brucei genome may be made up of VSG 
genes or pseudogenes. All but one of these are 'silent' VSGs, as each trypanosome expresses only 
one VSG gene at a time. VSG is highly immunogenic, and an immune response raised against a 
specific VSG will rapidly kill trypanosomes expressing this VSG. However, with each cell division 
there is a possibility that one or both of the progeny will switch expression to a silent VSG from the 
archive. The frequency of such a switch has been measured to be approximately 1:100. This new 
VSG will likely not be recognised by the specific immune responses raised against previously 
expressed VSGs. It takes several days for an immune response against a specific antigen to develop, 
giving trypanosomes which have undergone VSG coat switching some time to reproduce 
unhindered. Repetition of this process prevents extinction of the infecting trypanosome population, 
allowing chronic persistence of parasites in the host. The clinical effect of this cycle is successive 
'waves' of parasitaemia (trypanosomes in the blood). 
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Fig. 3: Sinuous variation in parasite population due to immune evasion strategies of the parasite 
 
Life cycle 
 
By taking a blood meal metacyclic trypomastigotes in the saliva of the tsetse fly are inoculated to 
the mammalian host (e.g. humas, cattles) causing some days later a local inflammation reaction 
with a typical erythema. Swelling of lymph nodes occurs at the site of infection  and  trypanosomes 
undergo cell cycle re-entry and a morphological change to proliferative, long-slender bloodstream 
trypanosomes (or trypomastigotes) followed by asexual multiplication by binary division.  
Finally the trypomastigotes are released via lymph vessels and lymph nodes into the blood 
circulation. 
A fluctuating fever occurs in the patient, synchronic with the parasitaemia. When density of 
trypanosome increases in the blood, transformation occurs to non-proliferative short stumpy forms 
(indicated by cell cycle arrest, raising mitochondrial activity and resistance to lysis by antibody). 
The population of long-slender, short stumpy and transition stage forms is being described as 
pleomorphic. The short-stumpy trypanosomes are ready for re-transmission to the tsetse fly. 
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Fig. 4: T. brucei life cycle (WHO) 
 
Only weeks or months after infection parasites cross the blood-brain barrier and invade the CNS, 
where they cause a chronic encephalopathy. Symptoms are headaches, disorder of the sleeping 
rhythm (therefore the disease has got the second name “sleeping sickness”), apathy, somnolence 
and in the latest stage coma and lead finally, if untreated, to death of the patient. 
A physical characteristic of the fist stage of the disease is a swelling of lymph nodes in the neck, 
known as “Winterbottom sign”. The diagnosis however is complex and elaborate, the therapy 
complicated and expensive and can in addition be perilous for the patients. 
When re-entered in an insect host short-stumpy trypanosomes enter the fly’s midgut. Shortly 
afterwards they transform into procyclic trypomastigotes and reproduce asexually by binary fusion. 
Then they move to the anterior part of the midgut and elongate to produce mesocyclic 
trypomastigotes that will migrate to the salivary glands to quickly develop into epimastigotes (Van 
Den Abbeele et al., 1999), attached by their flagella to the wall of the glands. 
 
 
Energy metabolism 
 
Like many organisms, trypanosomes have to perform metabolic adaptation to highly varying 
environmental conditions encountered during their complex life cycle, including  the transmission 
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between an insect and a mammalian host. In both organisms they transit through different parts of 
the body, each time being exposed to different environmental conditions. 
Trypanosomes feed by taking up nutrients, through their plasma membrane, from the body fluids of 
the host, by using specific nutrient transporters and by endocytosis. 
The major human pathogenic stage of T. cruzi, the amastigotes which reside in the cytoplasm of the 
host cells, bases its energy metabolism largely on carbohydrates being provided as freely accessible 
sugar phosphates and Leishmania amastigotes, the pathogenic stage residing in phagolysosomes of 
macrophages, rely more on fatty-acid and amino-acid metabolism. In contrast, bloodstream form T. 
brucei is up taking glucose as energy substrate from the fluids of its host. 
The metabolism in different life-cycle stages differs considerably. The BF is completely dependent 
on glycolysis for its ATP supply. In contrast, glycolysis is less important in PF trypanosomes, 
which have a more oxidative form of metabolism with their well-developed mitochondrion. 
Probably in order to refine their adaptation capacity trypanosomes have developed a special form of 
metabolic compartmentalization in which glycolysis features prominently. Whereas in most 
organisms glucose metabolism is taking place exclusively in the cytosol, the larger part of 
glycolysis in trypanosomatids takes place in specialized organelles hence called glycosomes 
(Hannaert et al., 2003, Michels et al., 2006). This unique form of glycolysis compartmentalization 
was originally found in T. brucei (Opperdoes and Borst, 1977), but was subsequently also 
discovered in T. cruzi and various Leishmania species, as well as parasites of other vertebrates, 
invertebrates and plants, all belonging to the Kinetoplastida. Glycosomes may comprise up to 90% 
of its protein content as glycolytic enzymes and bloodstream trypanosomes contain approximately 
65 of these organelles. 
These organelles contain, in addition to the enzymes for the first seven glycolytic steps (Fig 5), the 
enzymes of the oxidative branch of the pentose phosphate pathway (PPP). 
Despite their prominent glycolytic function and the lack of catalase, glycosomes belong to the 
peroxisome family, taking in account the single phospholipid bilayer, the fact that they do not 
contain DNA and the similar process of biogenesis involving homologous proteins, the so called 
peroxins. Proteins imported into glycosomes and peroxisomes require a peroxisome-targeting signal 
(PTS). 
This compartmentalization of glycolysis in the glycosome seems to be important for metabolic 
homeostasis. Activities of glycolytic enzymes such as hexokinase (HK) and phosphofructokinase 
which are normally highly regulated seem to be unregulated in trypanosomes (Nwagwu and 
Opperdoes, 1982). In yeast mutants it has been shown that absence of active regulation of these 
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enzymes may lead to unrestricted accumulation of glycolytic intermediates which could be highly 
toxic for the cell. 
Mathematical modelling showed that improper compartmentalization of glycolytic enzymes in 
trypanosomes would also cause uncontrolled accumulation of hexose 6-phosphates, because the 
kinases are responding to the glycosomal ATP/ADP ratio that is usually low but the enzymes would 
sense the high cytosolic ATP/ADP ratio in the case of defect in glycosomes or improper 
compartmentalization and consequently they would be activated without being restrained by the 
product for which the trypanosome enzymes are not sensitive. Indeed, experimentally it has been 
confirmed that correct compartmentalization of glycolytic enzymes inside glycosomes is essential 
for the survival of bloodstream form T. brucei (Guerra-Giraldez et al., 2002). Abundance of glucose 
in the bloodstream and a high rate of aerobic glycolysis (with pyruvate as end product) allow 
bloodstream form T. brucei to proliferate rapidly. ATP is produced exclusively by glycolysis: two 
molecules ATP per molecule glucose are consumed. 
Glycolysis in trypanosomes is considered a validated drug target because these parasites are 
completely dependent on the conversion of glucose into pyruvate for their ATP supply when living 
in the mammalian bloodstream (Bakker et al., 2000, Verlinde et al., 2001). The seven enzymes 
involved in the conversion of glucose into 3-phosphoglycerate are present inside the glycosomes, 
while those catalyzing the last part of the pathway are localized in the cytosol (Fig. 5) (Opperdoes 
and Borst, 1977). 
Knockdown of the expression of glycolytic enzymes by RNA interference (RNAi) resulted in death 
of the parasites (Albert et  al., 2005).  
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Fig. 5 : Schematic representation of glycolysis in the bloodstream form of T.brucei. (Under aerobic 
conditions, glucose is converted into pyruvate. Under anaerobic conditions equimolar amounts of glycerol 
and pyruvate are produced) (Michels et al., 2006) 
 
 
The PPP is also very important for trypanosomes since it provides NADPH, required for many 
biosynthetic and detoxification reactions and active in protection against oxidative stress, and 
ribose, essential for nucleotide biosynthesis. Enzymes of this pathway have a dual localization: in 
the cytosol and in glycosomes (Duffieux F et al., 2000, Michels P.A. et al., 2006). Both the 
dehydrogenases of the PPP are considered valid drug targets against HAT, indeed RNAi 
experiments have shown that they are essential for growth of T. brucei bloodstream forms (Barrett 
et al., 2002, Cordeiro et al., 2009) Inhibitors of 6-phosphogluconate dehydrogenase (6PGDH) have 
been found with trypanocidal activity  (Hanau S. et al., 2004) and 6PGDH inhibition leads to 
accumulation of 6-phospho-gluconate, which is a competitive inhibitor of GPI in glycolysis  
(Marchand M. et al., 1989). 
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Defence against oxidative stress in Trypanosomes 
 
Throughout their life cycle trypanosomes are exposed to oxidative stress imposed by reactive 
oxygen species (ROS) derived from its own aerobic metabolism, and from the host immune 
response. 
In nearly all organisms, glutathione and glutathione reductase are involved in the maintenance of 
the intracellular reducing environment. This is important for the reduction of disulphides, the 
detoxification of hydroperoxides and the synthesis of DNA precursors (Schirmer et al., 1987, 
Penninckx and Elskens, 1993). Kinetoplastid protozoa, highly sensitive to oxidative stress caused 
by reactive oxygen species, lack glutathione reductase (Fairlamb and Cerami, 1985) and many of 
the functions ascribed to glutathione and glutathione reductase appear to have been taken over by 
N1,N8-bis(glutathionyl)spermidine (trypanothione) and trypanothione reductase (TRYR) (Fairlamb 
et al., 1985; Fairlamb and Cerami, 1992).  
Trypanothione is kept reduced by trypanothione reductase using NADPH and the major source of 
this reduced coenzyme seems to be the PPP.  
An other important enzyme seems to be lipoamide dehydrogenase producing free thiols with 
antioxidant power in the form of dihydrolipoate. In leishmania 4-mercaptohistidine (ovothiol A) is 
an other strongly low-molecular-weight thiol (Krauth-Siegel and Schoneck, 1995).  
 
 
Anomeric specificity of enzymes 
 
α- and β-anomers of aldose sugars can spontaneously interconvert. D-Glucose and D-glucose 6-
phosphate (Glc6P) are examples of hexose carbohydrates that, in solution, undergo spontaneous 
interconversion between α and β anomeric  forms. This reaction, known as mutarotation, happens at 
slow rates when compared to the corresponding enzyme-assisted process. Rate constants for 
spontaneous mutarotation of glucose and glucose 6-phosphate are 0.015 min−1 and 0.09 min−1, 
respectively (Livingstone et al., 1977). In equilibrated solutions of D-glucose and D-Glc6P, the 
ratio of α to β anomer is 33:66 and 20:80, respectively. 
Several enzymes of carbohydrate metabolism show different levels of anomeric selectivity, which 
can vary from a moderate preference to full specificity. Hexokinases have a preference for α-
glucose; yeast glucose-6-phosphate dehydrogenase (G6PDH) is specific for β-D-Glc6P; phospho-
glucose isomerase (PGI) is specific for α-Glc6P while it is specific for β-D-fructose-6-phosphate, 
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both as a substrate and a product, and has an anomerase-like activity for both these hexose-6-
phosphate, Glc6P and fructose-6P (Salas et al., 1965, Willem et al, 1992) )(Scheme 1 and  Fig. 6). 
Very recently, the crystal structure of the T.cruzi ATP-dependent glucokinase (GlcK) complexed 
with glucose was determined (Cordeiro et al., 2007). Whereas in all available exokinase (HK) 
crystal structures, glucose was found as an α-anomer, in line with the known general preference of 
HKs for this anomer (Malaisse, 2003), it could be concluded from the electron density of the T. 
cruzi GlcK structure that the bound D-glucose was in the β-configuration. 
Kinetic assays with α- and β- D-glucose further confirmed a moderate preference of the T. cruzi 
GlcK for the β-anomer (Cordeiro et al., 2007). The reason for the presence of a GlcK in these 
parasites (also in Leishmania major, but absent from T. brucei, (Caceres et al., 2007)) in addition to 
a HK, is not clear yet. 
Glycolysis is, according to the literature, highly specific for α-sugars, whereas the PPP would be 
highly specific for β-sugars. 
Notably in Trypanosomes, the first enzyme specific of each pathway, following the shared HK, 
displays high anomeric specificity: PGI for α-Glc6P, G6PDH for β-Glc6P. It could therefore be 
imagined that the GlcK of T. cruzi and L. major serves primarily to feed the PPP, and HK the 
glycolytic pathway.  
If, however, T. brucei has only a HK, but no GlcK, it would need an additional enzyme, to get the 
β-Glc6P for its PPP, implicated in this step. 
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Fig. 6 : Schematic representation of anomeric specificity of enzymes involved in the metabolic cross-road at 
the level of glucose-6P. PGM, phosphoglucomutase, PGI, glucose phosphate isomerase, PFK, 
phosphofructokinase, G6PDH, glucose-6-P dehydrogenase 
 
 
Hexose-6-phosphate mutarotase 
 
Recently determined structure-based data give evidence that the S. cerevisiae ymr099c gene product 
exhibits hexose-6-phosphate mutarotase (H6PM) activity on Glc6P, galactose 6-phosphate (Gal6P) 
and mannose 6-phosphate (Man6P) (Graille et al., 2006). This study was based on the previous 
finding of an unidentified enzyme with Glc6P mutarotase  activity (Wurster and Hess, 1972). 
Recently the genome sequencing project of T. brucei (927 strain) (Berriman et al., 2005) has been 
completed and provides a great tool to find out more about the complexity of metabolic pathways. 
Using the yeast H6PM sequence, a homologous sequence could be detected in the databases of T. 
cruzi, L. major and T. brucei. 
 49 
 
In a  previous study of comparative proteomics of bloodstream and procyclic T. brucei glycosomes 
various proteins have been identified by nanoLC-MS/MS, which are annotated in GeneDB as 
hypothetical proteins. Among those a protein (GeneDB accession number Tb927.4.1360) found in 
procyclics, that the proteomics researchers annotated as ‘aldose-1-epimerase-like’ and with a PTS1 
localisation signal could be detected (Colasante et al., 2006). 
Indeed, an aldose-1-epimerase motif was predicted by Pfam database. However, because of its 
similarity with yeast YMR099c, with residues involved in the 6-phospho group  binding conserved, 
it seems likely that it is a H6PM, suggesting that mutarotation of sugar phosphates plays an 
important role in T. brucei metabolism to provide the PPP with its substrate. 
The low spontaneous mutarotation rates and the anomer selectivity of key enzymes of sugar 
metabolism highlight the importance of mutarotases to support fast metabolic fluxes.  
 
 
State of the art on H6PM from T. brucei 
 
The T. brucei sequence homologous to yeast H6PM, was cloned and expressed in E. coli (Moebius,  
thesis). It appears that T. brucei H6PM exists as a monomer of 32.5 kDa and a dimer of 63,2 kDa. 
The dimeric form is much more concentrated, but there is decomposition of the dimeric state over 
time. 
The overall similarity between the yeast and T. brucei sequence is up to 31.2 % and the active site 
residues and other motifs for the binding of the hexose 6-phosphate molecule and catalysis by 
the yeast enzyme are found to be conserved in the trypanosomatid sequence (Fig. 7). Site-directed 
mutagenesis could show that in L. lactis galactose mutarotase, His170 and Glu304 play the role 
of catalytic acid and base, respectively (Thoden et al., 2003). In the yeast Glu203 may act as a 
general base through deprotonation of the anomeric O1 hydroxyl group while His159 as the acid by 
protonating the O5 sugar ring oxygen. Besides the homology in residues for the catalytic 
mechanism, there are also especially two arginines (“arginine clamp” formed by Arg57 and Arg86, 
yeast numbering) present in the trypanosomatid sequence important for accession and binding of 
the phosphate group of the hexose 6-phosphate molecule. This feature makes the H6PMs differ 
from the homologous aldose 1-epimerases acting on hexoses normally and not containing positive 
side chains in the needed conformation to host a phosphate group. 
Regarding the global three-dimensional structure the H6PM sequence presents the motif of aldose-
1-epimerase like galactose mutarotase, which is also present in yeast H6PM. These enzymes are 
beta proteins with a supersandwich fold (Fig. 8, Graille et al. 2006). 
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Fig. 7: Complex of yeast PGM bound to β-glucose 6P. 
 
 
Fig. 8: Stereoview ribbon representation of yeast H6PM (Graille et al. 2006) 
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A system to knock down the gene by RNAi has been produced in the laboratory of Paul Michels at 
UCL, Brussels, and by a first study it seems that the enzyme is important for growth of the 
procyclic trypanosomes (Moebius, thesis). 
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AIM OF THE STUDY 
 
The objective of this work was to well characterize the enzyme and elucidate its function in 
T.brucei metabolism. Above all the aim has been to assess the importance of the putative H6PM for 
the insect and mammalian stage of the parasite, for bloodstream form in particular related to 
oxidative stress defence. 
The approach is to use T. brucei cell lines (BF and PF) where H6PM is knocked-down by RNAi 
and to check the effect on the viability of trypanosomes and, for bloodstream form, on their 
susceptibility to oxidative stress, comparing the results to cell line where G6PDH is depleted and a 
significant growth reduction was the result, indicating the importance of this pathway. 
Furthermore, more generally parasite-specific features of this enzyme should be  unravelled,  
notably  to study its inter-relation with the PPP and glycolysis. It might also serve as potential  
target for new drugs. Compounds may then be developed that will inhibit the enzyme without 
having an effect on enzymes of the human host. Such inhibitors could serve as leads in the 
development of new drugs against the diseases caused by the parasites. 
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MATERIALS AND METHODS 
 
 
Overexpression of the T. brucei enzyme in E. coli. 
 
pET28, which has the bacteriophage T7 RNA polymerase promoter, is the expression plasmid while 
the pJET1/blunt is the cloning vector. 
Plasmid pET28 was transformed into E.coli strain BL21 (DE3). BL21 (DE3) are E. coli cells with 
the phage DE3 encoding T7 RNA polymerase under the control of the lacUV5 promoter; they 
represent an optimal system for expression of recombinant proteins in conjunction with pET 
plasmids. Plasmid directs the synthesis of a construct with an N-terminal 20 residues long extension 
including six adjacent histidine residues (‘His6-tag’). 
A single transformed colony was grown overnight at 37°C in LB/kan (Luria Bertani broth plus 
kanamycin). This preculture was then used to inoculate 250 ml of freshly prepared ZYM-5052 
Medium (1 % (w/w) Tryptone, 0.5 % (w/v) Yeast Extract, 
25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl , 5 mM Na2SO4 , 2 mM MgSO4 , 0,5 % Glycerol, 
0,05 % Glucose,0,2% Lactose) supplemented with 30 µg/ml kanamycin at 20°C for 17 hours. 
 
 
Purification of recombinant protein 
 
Cells were harvested by centrifugation (5000 rpm, 20 min), resuspended in 10 mL of cell lysis 
buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl, 10 mM imidazole, 2 mM β-mercaptoetanol) and a 
complete protease inhibitor cocktail (Roche Applied Science). Cells were disrupted by three 
passages through a SLM-Aminco French pressure cell (SLM Instruments, Inc.) at 6.9 MPa. Nucleic 
acids were degraded by incubation of the lysate with 100 units of DNase (Roche Applied Science) 
for 20 min at 4°C. Cell debris and insoluble material were then spun down (9000 rpm, 10 min).The 
supernatant was added to a 1,5 ml of Ni-NTA.agarose resin (Quiagen) and was allowed to bind to 
the resin in a batch format for 1 h at 4°C with gentle agitation. The resin with bound protein was 
then transferred to a column and washed extensively with wash buffer (20 mM imidazole) and 
eluted with elution buffer (250 mM imidazole). Samples were analyzed on 10% SDS-PAGE gels. 
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Determination of protein concentration  
 
Protein content was determined with the spectrophotometer at 280 nm, assuming that a solution 
containing 1mg/ml of protein have an absorbance of 1 O.D. 
Otherwise the Bradford assay for protein quantification was used. 
 
 
Electrophoresis in polyacrylamide gel (SDS PAGE) 
  
4 µg/µl of enzyme are denatured at 100°C for 5 minutes in the presence of the reducing agent 2-
mercaptoethanol and loaded onto a 10 % polyacrylamide gel. The migration has been made into 
electrophoresis buffer during 45 minute with an amperage of 25 mA. The proteins were coloured 
with a solution of Comassie blue (0.008% p/v Comassie Brillant Blue G-250, 45 mM HCl) by 
warming the gel in a microwave oven for about 30-60 sec. 
Destaining is done in bidistilled water at room temperature gently shaking. 
 
 
Storage of the enzyme 
 
Due to its fast inactivation after purification, the enzyme was stored in different conditions to 
determine the best one to preserve its activity.  
The enzyme was stored in the presence of 50% glycerol at -20°C and in 3.2M ammonium sulphate 
(or more till 80% saturation) at 4°C. 
 
 
Kinetic studies 
 
Normally it was used for kinetic measurements directly after purification, because of the enzyme 
instability : a time-dependent decrease of activity was observed after purification. 
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Preparation of α-glucose 
 
A saturated solution of D-glucose in water is prepared at 45°C and then conserved at 4°C for a long 
period till crystallisation of α-glucose (Thomson and Wolfrom, 1962). 
 
 
G6PDH-Assay (Wurster and Hess, 1972, Graille et al., 2006) 
 
In a first assay system to determine the specificity of H6PM for Glc6P (Fig. 9), any formation of β-
Glc6P from α-glucose via yeast HK (=HXK) and H6PM could be followed by measuring the 
increase in absorbance at 340 nm in a Jenway 6715 UV-vis  spectrophotometer caused by the 
generation of NADPH, coupled to the conversion of β-Glc6P into D-glucono-1.5-lactone 6-
phosphate by G6PDH. Using instead T. cruzi glucokinase in place of exokinase the formation of β-
Glc6P from β-glucose could be followed. Measurements were performed at 20°C in 0.1 M 
triethanolamine (pH 7.6), 2.5 mM MgCl2, 5 mM ATP, 0.64 mM NADP+, 1.4 U of yeast G6PDH, 2 
U of HK and 20 mM of either α- or equilibrated glucose.  
 
 
 
Fig. 9 : Enzymatic assay coupled to G6PDH activity and either HXK or TcGlcK activity or both. 
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RNA interference  
 
RNA interference is a recently recognized cellular process in which the presence of a double 
stranded RNA (dsRNA) causes single stranded RNA of the same sequence to be degraded (Ullu et 
al., 2004). RNAi belongs to a family of related processes referred as post transcriptional gene 
silencing (PTGS). These pathways were first observed in plants and fungi, since then in 
trypanosomes, Drosophila and other organisms.  
The RNAi pathway is initiated by the enzyme Dicer, which cleaves long dsRNA into short 
fragments of 21-25 nucleotides, termed small interfering RNAs (siRNA). Then only sense  strand of 
each fragment in incorporated into the RNA-induced silencing complex (RISC) that recognizes 
complementary mRNA molecules and degrades them, resulting in substantially decreased levels of 
protein translation and effectively turning off the gene (Fig. 10). 
 
 
 
 
Fig. 10 : Schematic representation of the RNAi pathway in T. brucei 
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RNAi construct 
 
A T. brucei specific vector phD677 was used to generate stable bloodstream and procyclic cell lines 
for the Tetracylin-inducible expression of a double-stranded RNA of putative H6PM. Transgenic 
trypanosomes (427-strain) that constitutively express the Tet repressor were used for transfection. A 
DNA fragment containing the full-length gene flanked with HindIII and BamHI restriction sites at 
the 5’- and 3’- ends, respectively, was introduced into vector pHD677 (Biebinger et al., 1997). This 
places the gene under the control of a T. brucei procyclic acidic repetitive protein promoter (PARP) 
to which the tet operator has been fused. The vector has also a hygromycin gene, which will be 
constitutively expressed in trypanosomes, allowing the selection of positive clones (Fig. 11). The 
recombinant construct is introduced into non-transcribed spacers of the ribosomal RNA repeat. 
 
 
 
Fig. 11: pDH677 vector. rRNA, intergenic region targeting sequence; the two black circles represent the 
tetracycline repressor bound to the Tet operator; VSG, constitutive VSG promoter; HYG, hygromicine 
resistance gene 
 
 
Double stranded RNAs are produced as hairpin molecules (Fig. 12) by transcription of constructs 
comprising two complementary fragments of the coding regions of each gene linked by an 50 bp 
spacer and arranged as a direct inverted repeat.These constructs were obtained by amplification of a 
sense and an antisense fragment of H6PM using designed primers. The RNAi constructs were 
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prepared for chromosomal integration in the transcriptionally silent ribosomal RNA gene repeat 
spacer. 
 
 
 
 
Fig. 12: hairpin formation of double stranded RNA after transcription 
 
 
Linearization of plasmid 
 
Linearization should be carried out by one hour digestion with 1µl Not1 (1 U/µl) and controlled by 
agarose gel electrophoresis. Transfection was carried out in triplicate using 10 μg of DNA each 
time, therefore quantification should be performed after the purification step to assure a total 
amount of at least 30 µg of DNA. 
 
Spectrophotometric determination of DNA concentration 
 
The DNA concentration was assayed both at 260 nm and 280 nm: 
 
DNA Concentration (μg/ml) = A280nm x   50 μg/ml 
 
The ratio OD260/OD280 must be ≥ 1.7 for pure preparation of DNA, if the ratio is < 1.7 it means that 
in the sample there is protein contamination. 
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Electrophoresis in agarose gel  
 
The agarose gel was prepared in buffer TAE (0,04 M Tris, 1mM EDTA, 5 mM sodium acetate, 
taken to pH 7.5 with glacial CH3COOH) adding ethidium bromide 0,4 μg/ml. Before loading, 0.2 
volumes of  the following buffer: 0.25 % (p/v) bromine phenol dye, 100 mM EDTA, 50% (v/v) 
glycerol is added to the sample. After the electrophoretic run, DNA is seen by UVtransillumination, 
for the fluorescence effect of the ethidium bromide that binds to double stranded DNA. 
 
Transfection of trypanosomes and growth curve 
 
T. brucei bloodstream and procyclic trypanosomes were defrozen, diluted into medium and 
maintained for one week to obtain a stable  and well reproducing colture for transfection. 
Bloodstream form and procyclic form were grown in HMI-9 medium (Hirumi  et al., 1989) at 37°C 
and in SDM-79 at 28°C, respectively. 
The following transfection procedure is different for procyclic and bloodstream form of T. brucei 
and it will therefore be described apart. 
 
Bloodstream form transfection 
 
For transfection of bloodstream form trypanosomes, 15 ml of culture was harvested at a density of 2 
x 106 cells/ml, centrifuged at 2000 rpm. The pellet was washed once with 5 ml of Cytomix 
transfection buffer and resuspended in 1,2 ml of the same solution. The cells were then split and 
400µl (approximately 1 x 10 7cells/ml) were mixed each with 10 µg of DNA in a transfection 
cuvette and subsequently subjected to a single discharge by a Genetronics BTX FCM630 
electroporator with a 1.23 kV, 25 Ohm and 50 µF setting, to obtain a pulse with a time constant of 
about 260 µs. The cells were then rapidly diluted in 12 ml culture medium, supplemented with 20% 
FCS, and incubated overnight. After 24 hours the culture was diluted once by adding a 
concentration of 5µg/µl of hygromycine and split into 24 wells plate. Antibiotic-resistant cells were 
detectable about 5 days after. 
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Procyclic transfection 
 
For procyclic transfection 6 ml of a culture at 1 x 107 cells/ml were centrifuged 10 min at 2000 rpm, 
washed once with 3 ml ice-cold ZPMF Medium, and resuspended in this medium. 2 x 10 7  cells 
were mixed each with 10 µg of linearized DNA and incubated on ice in a 4mm electroporation 
cuvette for 10 min. Cells were then subjected to a single pulse by the electroporator set for a peak 
discharge of 1.8 kV, 25 Ohm and 50 µF, to give  pulse  with a time constant of 600-700 µs. After 
electroporation cells were rapidly diluted in 4.5 ml of SM-79 medium and incubated overnight. 
Subsequently the culture was diluted serially into 24 wells plate using 4.5 ml conditioned SDM-79 
medium (SDM-79 medium harvested from a procyclic culture at the exponential growth phase of 7-
9 x 10 cells/ml  after one to two days with a light orange colour; elements of this medium are 
necessary for transfected procyclic forms to recover and start growing) containing 100µg/ml 
hygromicine (to obtain final concentration of 50 µg/ml). 
Antibiotic-resistant cells were detectable about 7 days after. 
Positive clones could be selected after the induced period of time by the colour of the medium. Only 
trypanosomes that introduced the construct, gained antibiotic resistance and were able to grow in 
the medium, inducing a colour change in the medium from red (HMI-9) or dark orange  (SDM-79) 
to  yellow.  Then they could be stored at -80 °C in the appropriate medium containing 12 % 
glycerol or used for RNAi experiments. 
For induction of double-stranded RNA, cells were cultured in medium containing 1 g/ml of Tet (in 
DMSO) for bloodstream-form and 5 g/ml of Tet for procyclic-form cells.  
Tet induction has been repeated each 24 hours after counting and diluting and compared to non- 
induced RNAi cells and to WT trypanosomes. 
Cultured cells were diluted daily to 2•105cells/ml and 1•106 cells/ml for bloodstream- and procyclic-
form trypanosomes, respectively. 
Cell densities were determined using cell counting grids (Bürker-Türk, with a depth of 0.01 mm) 
and growth curves were plotted as the product of cell density and total dilution, versus time. 
 
RT-PCR 
 
It was performed only on blood-stream form RNAi cell line and WT, to determine how long after 
induction the levels of the RNA for H6PM decrease, to start oxidative injure test. 
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Total RNA was extracted with SV total RNA isolation system kit (Promega) from a 50 ml culture 
of bloodstream form WT and from the same amount of culture of RNAi cell line before tet 
induction (Non Induced) and after 12, 24, 36, 48, 72 and 96 hours induction. 
Amount and purity of RNA was determined by spectrophotometry  at 260 and 280 nm. 
RT-PCR was performed using 2µg of RNA with random hexamer primers. After a 5 min incubation 
at 70 °C, ribonuclease inhibitors and dNTP’s were added and reaction led for another 5 min at 25 
°C. 
Reverse transcriptase (Revert Aid H-first strand c-DNA synthesis kit Fermentas) was then used. A 
control was made without adding the enzyme (RT) to check absence of DNA contamination; a 
temperature profile was applied (10 min 25 °C, 60 min 42 °C, 10 min 70 °C).  
The produced cDNA was either stored at -20°C or immediately used for PCR. 
PCR reaction was carried out using GoTaq DNA Polymerase (5 µu/ µl) with green coloured loading 
buffer (Promega) and 1µg of cDNA for each PCR. Specific primers for H6PM (Table 1) were used 
to amplify a fragment of 350 bp and tubulin primers as a positive control. The PCR was cycled as 
written in Table 2. 
 
Table 1: H6PM PCR primers 
 
 
Table 2: PCR protocol 
 
RT-PCR_fw 5’ CGCGATTTGCTTGGACACG 3’ 
 
RT-PCR_rv 5’ CAACCGCCTTGGCGGCAGCAC3’ 
Step Cycles Temperature Time 
1 1 95 °C 3 minutes  
2 16 for Tubuline 
26 for H6PM 
 
95 °C 
62°C 
72°C 
30 seconds 
30 seconds 
30 seconds 
3 1 72°C 10 minutes 
4 1 4°C pause 
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PCR has been repeated three times. 
All samples have been loaded on 2% Agarose gel without ethidium bromide and stained afterwards 
with SyberGold for half an hour under light protection.  
Analysis has been carried out with KODAK Image Station in a semi quantitative way. Sum 
intensity of DNA for the enzyme and for the control protein were evaluated, background by the 
number of pixels taken in account were subtracted. The so obtained net intensity value for the 
protein was divided by that for tubuline and the logarithm was calculated. Three independent 
repetitions of PCR have been carried out and were analysed individually with KODAK Molecular 
Imaging Software and a mean value could be calculated. 
 
Hydroperoxide-sensitivity assay  
 
RNAi bloodstream trypanosomes grown for 96 hours in the presence and absence of tetracycline 
were diluted to 2•105cells/ml in HMI-9 with hygromycine. Also a WT population was diluted at the 
same cells density in HMI-9 medium without antibiotic. 
Then 25 µM and 125µM H2O2 was directly added to the cultures that were incubated at 37°C and 
5% CO2 . 
Cells viability was assessed after 6 and 24 hours by counting living parasites in a Burker chamber 
under the light microscope. Dead parasites were distinguished by morphological and motility 
criteria. 
As a control the same experiment was performed on a cell line transfected with a tet-inducible 
construct for glucose 6-posphate dehydrogenase (G6PDH) depletion. In this case the hydroperoxide 
bolus was added after a 24 hours induction. 
In a second group of experiments the procedure was standardized and optimized: bloodstream-form 
trypanosomes (wild-type cells and trypanosomes induced for RNAi) were grown in regular HMI-9 
medium. After different periods of time, cells were collected by centrifugation and resuspended in 
non-reducing medium (modified DMEM, i.e. no β-mercaptoethanol and cysteine). Then the cell 
density was determined. H2O2 was added at different concentrations and the cell suspensions were 
incubated for 1.5 h; then the cell density was determined again. The procedure was adapted from 
Krieger et al., 2000.    
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RESULTS 
 
 
Conditional depletion of H6PM levels by RNAi 
 
After transfection and dilution, the cells were left in culture, in a medium supplemented with 
antibiotic, for 5-7 days. Hygromycin resistance caused by expression of the marker gene on the 
introduced plasmid was used for selection of positive clones. Antibiotic resistant clones continued 
growing, while parasites not containing the vector died rapidly. For procyclics, three of the 24 
clones were positive and, after morphological analysis by light microscopy, one of them was 
selected for the further studies. For the bloodstream form, only one of the 24 clones was found 
positive and it was used for RNAi induction. 
 
 
Growth curves 
 
The growth of trypanosomes, transfected with a plasmid producing double-stranded RNA to 
decrease the enzyme levels, was determined for cells cultured in the absence (-TET) or presence 
(+TET) of the RNAi inducer tetracycline (1mg/ml for bloodstream-form trypanosomes and 5 mg/ml 
for procyclic cells). 
For both, bloodstream-form and procyclic trypanosomes, only a small change in the growth rate 
could be observed upon RNAi induction, compared to WT parasites. Strangely, induced and non-
induced trypanosomes follow the same growth rate  (Fig. 13 A and B). Usually, non induced cell 
lines grow at the same rate as WT. This anomalous behaviour could be due to the presence of some 
antibiotic tracks in fetal calf serum in the medium, otherwise it might suggest 'leakage' of the RNAi 
control (which sometimes has been reported). 
From growth curve it is not possible to determine exactly when RNA level for the protein starts to 
decrease significantly. 
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Fig. 13 : Effect of the intracellular depletion of putative tbH6PM by RNAi, on the growth of  
bloodstream form (A) and procyclic (B) T. brucei. In theY axis the log10  values of cumulative cell numbers 
are shown  
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RT-PCR 
 
PCR has been carried out (with primers described in Materials and Methods) on cDNA produced 
from RNA, isolated from bloodstream wild-type trypanosomes, and cells of a cell line, in which the 
putative tbH6PM was knocked-down by RNA interference, induced by tetracycline. 
A control (samples prepared without Reverse Transcriptase) was also subjected to PCR, to assure 
that false positive amplification results, from co-isolated DNA, are avoided. 
24 hours induction sample was not available because of the too low concentration after extraction.  
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Fig. 14 :  RT PCR analysis of bloodstream RNA, over a period of 96 hours induction, with Kodak 
Molecular Imaging Software and Excel 
 
 
As shown (Fig. 14 and 15) the RNA level could be reduced by continuous tetracycline induction. 
The reduction became significant after 72 hours of growth in the presence of inducer and continues 
until 96 hours. Three independent RT-PCRs have been carried out. The samples were also treated 
with tubuline primers to get an internal reference. The tubuline RNA amount remains constant 
during all the time (Fig. 15), so it can be assumed that  the  same  amount of cDNA has been used 
for RT-PCR. In the control (RNA without reverse transcriptase treatment) a faint band for tubuline 
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was only detectable in the wild-type cells, so that it can be concluded that no important 
contamination has taken place during RNA extraction. 
 
 
 
Fig. 15 :  Example of RT PCR in agarose gel 1.5%, stained with Sybr gold, imaged with KODAK program 
(control samples are not shown) 
 
 
Sensitivity of H6PM-RNAi bloodstream cell lines towards oxidative stress 
 
After 96 hours of induction with tetracycline (as determined from RT-PCR results) trypanosomes 
depleted of H6PM were diluted to a concentration of  5x105 cells/ml and  subjected to oxidative 
stress produced by addition of a bolus of  H2O2  at two different concentration: 25 μM and 125 μM. 
The oxidative stress was induced for 6 and 24 hours, after this period cells viability was assessed by 
using cell counting grids (Bürker-Türk, with a depth of 0.01 mm) at light microscope. 
As a control the same experiment was performed on a cell line transfected with a tet-inducible 
construct for glucose 6-posphate dehydrogenase (G6PDH) depletion. In this case the hydroperoxide 
bolus was added after 24 hours induction. 
For both cell lines the experiment were repeated twice.   
For the latter cell line, it seems (Fig. 16 A and B) that only the highest concentration of H2O2 has an 
effect on the growth rate of parasites and in particular on RNAi cells. Indeed trypanosomes 
challenged by 25μM H2O2 seem not to show a sensitivity increase to oxidative stress. 
Otherwise on H6PM RNAi cell line an effect on growth rate was observable also at the lowest 
concentration of hydroperoxide, but a dramatic effect on the growth rate is visible when the cells 
are subjected to the highest concentration of H2O2 ,this is more evident for the G6PDH RNAi cell 
line (Fig. 17 A and B and 16 B). 
WT NI  48h 72h 96h 
H6PM  Tub 
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Fig. 16: Susceptibility for H2O2 (25 μM and 125 μM) of bloodstream-form trypanosomes in which G6PDH 
is depleted by RNAi 
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Fig. 17:  Susceptibility for H2O2 (25 μM and 125 μM) of bloodstream-form trypanosomes in which H6PM is 
depleted by RNAi 
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Other experiments where the procedure was optimized using a fresh resuspension modified medium 
without reducing agents such as β-mercapotoethanol and cysteine, after 24-96 hours of induction of 
RNAi, showed not only reproducible results but that low oxidant concentration affect cells viability 
and can kill trypanosomes, almost at at a similar degree of G6PDH RNAi cells (Fig. 18 and 19).  
 
 
Fig. 18 : Control: The susceptibility for H2O2 of bloodstream-form trypanosomes in which glucose-6-
phosphate dehydrogenase is depleted by RNAi  (results of two independent duplicate experiments) 
 
 
 
Fig. 19 : The susceptibility for H2O2 of bloodstream-form trypanosomes in which the putative exose-6-
phosphate-1-mutarotase is depleted by RNAi  (results of two independent duplicate experiments) 
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Protein purification from E. coli 
 
During the enzyme preparation, we compared bacteria lysis by sonication and by the use of French 
press. The last method was necessary to obtain the enzyme. It is reported in fact that much protein 
remains in inclusion bodies, even if the sequence analysis predicts a good solubility. 
In Fig. 18 the purity degree is shown after 250 mM imidazole elution from the Nichel resin specific 
for proteins with a his tag. Gel filtration is necessary to obtain a definitive pure protein as shown in 
Fig. 19.  
 
 
 
 
 
Fig. 18    SDS-PAGE of T. brucei H6PM purified from E. coli. 
In the 2nd lane from the left the most pure fraction eluted by 250 mM imidazole from Ni-NTA resin. 
In the 1st lane ovalbumine (45 kDa), in the last lane the not-absorbed sample while in the 3rd and 4th lanes the 
initial eluted fractions, showing a lower purity degree. 
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Fig. 19    SDS-PAGE of T. brucei H6PM purified from E. coli. 
In the1st lane from the left pure protein is shown after gel-filtration on a Superdex 200 10/300 column, 
equilibrated with 50 mM phosphate buffer with 0.15 M NaCl pH 7.0. 
 
 
Activity assays 
 
To assay H6PM activity first we used as substrate glucose, which is supposed to be a mixture of α 
and β anomers with a higher β concentration, and, as coupled enzymes, a kinase and G6PDH from 
yeast which is specific for β−glucose 6P . 
When we used H6PM, in association with T. cruzi glucokinase which is specific for β−glucose 
(Scheme 2), we observed a very slight, not very significant, increase of activity, compared to the 
basal activity without mutarotase. 
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Scheme 2 
 
 
Instead, using H6PM, in association with yeast exokinase (Scheme 3), which has a preference for 
α-glucose, we could observe a clear doubling of activity. 
 
 
Scheme 3 
 
 
Same results were obtained using crystallysed α-glucose as starting substrate. 
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Stability of recombinant T. brucei H6PM 
 
Activity decay is very rapid, thus the assay was possible only the same day of purification. Enzyme 
inactivation was present either by leaving the enzyme at 4°C or in glycerol at -20°C. 
Precipitation of H6PM was possible only with a 80% ammonium sulphate saturation but again 
activity was irreversibly lost  after 1 night at at 4°C. 
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DISCUSSION 
 
 
Our results suggest that T. brucei H6PM is active on glucose-6P as substrate and not on glucose. 
Same data were obtained using a crystallised α-glucose, suggesting that in solution a very fast 
equilibrium between the two anomers is present.  
Data were previously reported of an activity also on glucose, when tested with an other type of 
assay, the so called “pyruvate kinase assay”, where the substrate is glucose and the coupled 
enzymes are T. cruzi glucokinase, pyruvate kinase and lactic dehydrogenase with addition of ATP, 
phosphoenolpyruvate, and NADH (Scheme 4)(Moebius thesis). 
 
 
 
 
 
Scheme 4 
 
 
Anyway T. brucei recombinant H6PM is a very unstable enzyme, thus very difficult to assay, even 
if, using a more pure enzyme, recovered by gel-filtration, might in future studies to improve the 
stability conditions.  
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Even if kinetic studies are certainly not exciting, striking results are obtained with RNAi of the 
studied enzyme in bloodstream trypanosomes. Here the exciting first results are reported, and 
further optimized studies using a fresh resuspension modified medium without reducing agents such 
as β-mercapotoethanol and cysteine, after 72-96 hours of induction of RNAi.  
Expression knockdown of the putative G6P-1-epimerase by RNAi, has a small effect on growth of 
bloodstream-form T. brucei under normal conditions, but a dramatic effect when the cells are 
subjected to oxidative stress. H2O2 concentrations that have hardly any effect on wild-type cells 
affect already non-induced cells (suggesting 'leakage' of the RNAi control) and kill the cells upon 
induction.   
Data suggest indeed a role for this putative G6P-1-epimerase, whose better name is hexose-6P 
mutarotase, in feeding the pentose phosphate pathway (PPP).  
So the conclusion is that the H6PM is important for oxidative defence, probably by accelerating the 
anomeric conversion of G6P so that the flux through the PPP can increase. 
Data also confirm that G6PDH and more, PPP, is a good target to hit in African trypanosomes, but 
the upstream metabolic enzyme H6PM could be hindered too, in search of new approaches to fight 
these parasites, which often develop resistance to the actual used drugs.  
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